Coexistence of HBsAg/Anti-HBs and HBeAg/Anti-HBe in Sudanese Patients with Chronic Hepatitis B Virus Infection: A Cross-Sectional Study

ORIGINAL ARTICLE
Taqwa Hashim, Nmarig Osman, Afraa Abd-Alazeem, Anass M. Abbas, Manar G. Shalabi, Shawgi A Elsiddig, Ayman Ali Mohammed Alameen, Lienda Bashier Eltayeb, Asaad Ma. Babker, Hatem Mohamed, Rania Saad Suliman, Mustafa Eltigani Yassin

 
International Journal of Biomedicine. 2023;13(4):281-285.
DOI: 10.21103/Article13(4)_OA8
Originally published December 5, 2023

Abstract: 

Background: Seroconversion of hepatitis B surface antigen (HBsAg) to hepatitis B surface antibody (anti-HBs) is a recognized goal of HBV therapy. This dynamic transition responsible for the coexistence of HBsAg and anti-HBs is rarely detected in clinical cases. However, with vaccination and the use of various antiviral drugs, as well as the development of new medical technologies, recognizing the coexistence of HBsAg and anti-HBs has become more common. In addition, mutations in viral genomes, immune status, and human genetic factors may also contribute to such coexistence. The current study was designed to determine the prevalence of the coexistence of HBsAg and anti-HBs and HBeAg and anti-HBe in CHB patients in Sudan.
Methods and Results: This was a descriptive cross-sectional study conducted in Khartoum state from November 2018 to January 2019. The study included 70 HBV-infected patients who were positive for HBsAg for more than six months. Blood samples were tested for HBsAg/Anti-HBs and HBeAg/Anti-HBe using Commercial ELISA Kits (Foresight, United Kingdom) and (PRECHEK, USA). Demographic data were collected using a structured questionnaire, and any antiviral agent and laboratory results were also recorded for each participant. The current study showed that one case (1.4%) was reactive for the coexistence of HBsAg/HBsAb and two cases (2.8%) for the coexistence of HBeAg/HBeAb. There was no statistical difference between the coexistence of HBsAg/HBsAb and HBeAg/HBeAb with age, gender, residence, and treatment status.
Conclusion: Our study indicates that the frequencies of the coexistence of HBsAg/HBsAb and HBeAg/HBeAb among Sudanese patients with chronic HBV infection were low compared to previous studies in a different population.

Keywords: 
hepatitis B virus • HBsAg • HBeAg • anti-HBs • anti-HBe
References: 
  1. World Health Organization. Global Hepatitis Report, 2017. Geneva. Available from: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.aidsdatahub.org/sites/default/files/resource/who-global-hepa...
  2. Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat. 1997;4 Suppl 1:11-20. doi: 10.1111/j.1365-2893.1997.tb00155.x.
  3. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini SA, Fyfe J, Sozzi T, Jackson DC. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology. 2002 Feb 15;293(2):305-13. doi: 10.1006/viro.2001.1246.
  4. Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol. 2005 Feb;32(2):102-12. doi: 10.1016/j.jcv.2004.10.008.
  5. Colson P, Borentain P, Motte A, Henry M, Moal V, Botta-Fridlund D, Tamalet C, Gérolami R. Clinical and virological significance of the co-existence of HBsAg and anti-HBs antibodies in hepatitis B chronic carriers. Virology. 2007 Oct 10;367(1):30-40. doi: 10.1016/j.virol.2007.05.012. 
  6. Kohno H, Inoue T, Tsuda F, Okamoto H, Akahane Y. Mutations in the envelope gene of hepatitis B virus variants co-occurring with antibody to surface antigen in sera from patients with chronic hepatitis B. J Gen Virol. 1996 Aug;77 ( Pt 8):1825-31. doi: 10.1099/0022-1317-77-8-1825.
  7. Mimms L. Hepatitis B virus escape mutants: "pushing the envelope" of chronic hepatitis B virus infection. Hepatology. 1995 Mar;21(3):884-7. doi: 10.1002/hep.1840210341.
  8. Brunetto MR. Chance and necessity of simultaneous HBsAg and anti-HBs detection in the serum of chronic HBsAg carriers. J Hepatol. 2014 Mar;60(3):473-5. doi: 10.1016/j.jhep.2013.12.001.
  9. Pondé RA. Atypical serological profiles in hepatitis B virus infection. Eur J Clin Microbiol Infect Dis. 2013 Apr;32(4):461-76. doi: 10.1007/s10096-012-1781-9.
  10. Pondé RA. The underlying mechanisms for the "simultaneous HBsAg and anti-HBs serological profile". Eur J Clin Microbiol Infect Dis. 2011 Nov;30(11):1325-40. doi: 10.1007/s10096-011-1240-z. 
  11. Ding F, Yu HG, Li YX, Cui N, Dai JF, Yu JP. Sequence analysis of the HBV S protein in Chinese patients with coexisting HBsAg and anti-HBs antibodies. J Med Virol. 2015 Dec;87(12):2067-73. doi: 10.1002/jmv.24273.
  12. Seo SI, Choi HS, Choi BY, Kim HS, Kim HY, Jang MK. Coexistence of hepatitis B surface antigen and antibody to hepatitis B surface may increase the risk of hepatocellular carcinoma in chronic hepatitis B virus infection: a retrospective cohort study. J Med Virol. 2014 Jan;86(1):124-30. doi: 10.1002/jmv.23779.
  13. Lee BS, Cho YK, Jeong SH, Lee JH, Lee D, Park NH, Ki M; Korean Hepatitis Epidemiology Study Group. Nationwide seroepidemiology of hepatitis B virus infection in South Korea in 2009 emphasizes the coexistence of HBsAg and anti-HBs. J Med Virol. 2013 Aug;85(8):1327-33. doi: 10.1002/jmv.23594.
  14. Lada O, Benhamou Y, Poynard T, Thibault V. Coexistence of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of "a" determinant variants. J Virol. 2006 Mar;80(6):2968-75. doi: 10.1128/JVI.80.6.2968-2975.2006.
  15. Liu W, Hu T, Wang X, Chen Y, Huang M, Yuan C, Guan M. Coexistence of hepatitis B surface antigen and anti-HBs in Chinese chronic hepatitis B virus patients relating to genotype C and mutations in the S and P gene reverse transcriptase region. Arch Virol. 2012 Apr;157(4):627-34. doi: 10.1007/s00705-011-1215-5.
  16. Chen Y, Qian F, Yuan Q, Li X, Wu W, Guo X, Li L. Mutations in hepatitis B virus DNA from patients with coexisting HBsAg and anti-HBs. J Clin Virol. 2011 Nov;52(3):198-203. doi: 10.1016/j.jcv.2011.07.011.
  17. Gerlich WH. The enigma of concurrent hepatitis B surface antigen (HBsAg) and antibodies to HBsAg. Clin Infect Dis. 2007 May 1;44(9):1170-2. doi: 10.1086/513296. 
  18. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370-398. doi: 10.1016/j.jhep.2017.03.021.
  19. Horvat R, Tegtmeier G. Hepatitis B and D Viruses. In Murray P R, Baron E J, Jorgensen J H, Landry ML, and Pfaller M A. Manual of Clinical Microbiology,9th ed, 2015, 2, 1641-1659.
  20. Liu Y, Zhang L, Zhou JY, Pan J, Hu W, Zhou YH. Clinical and Virological Characteristics of Chronic Hepatitis B Patients with Coexistence of HBsAg and Anti-HBs. PLoS One. 2016 Jan 11;11(1):e0146980. doi: 10.1371/journal.pone.0146980. 
  21. Mudawi HM. Epidemiology of viral hepatitis in Sudan. Clin Exp Gastroenterol. 2008;1:9-13. doi: 10.2147/ceg.s3887. Epub 2008 Dec 11. PMID: 21677820; PMCID: PMC3108625.
  22. Abbas I, Abbas A, Shalabi M, Mohamed H, Arjabey AMM, Babker AM, Al Fadhil AO. Molecular Characteristic of Dengue Virus against its Outbreak response of Red Sea State, Eastern Sudan-2020. Open Access Macedonian Journal of Medical Sciences. 2022;(10):228–231
  23. M Abbas A, Shalabi MG, A Elsiddig S, Eltahir Z, M A Babker A, G Ahmed H. Evaluation of Angiogenesis by Using CD105 and CD34 in Sudanese Breast Cancer Patients. Pak J Biol Sci. 2021 Jan;24(11):1144-1151. doi: 10.3923/pjbs.2021.1144.1151. 
  24. Fagere MO, Elsiddig SA, Abbas AM, Shalabi MG, Babker AMA. Serous Effusion Cytology in Sudanese Patients. International Journal of Biomedicine. 2022;12(1):160-163. doi:10.21103/Article12(1)_OA20
  25. Gorish BMT, Saeed HA. Frequency of HBV among Hepatocellular Carcinoma Patients in Khartoum State, Sudan. J Carcinog Mutagen. 2018;9:320. doi: 10.4172/2157-2158.1000320
  26. Zhang JM, Xu Y, Wang XY, Yin YK, Wu XH, Weng XH, Lu M. Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection. Clin Infect Dis. 2007 May 1;44(9):1161-9. doi: 10.1086/513200. 
  27. Rabbi FJ, Rezwan MK, Shirin T. HBeAg/anti-HBe, alanine aminotransferase and HBV DNA levels in HBsAg positive chronic carriers. Bangladesh Med Res Counc Bull. 2008 Aug;34(2):39-43. doi: 10.3329/bmrcb.v34i2.1173. 
  28. Pu Z, Li D, Wang A, Su H, Shao Z, Zhang J, Ji Z, Gao J, Choi BC, Yan Y. Epidemiological characteristics of the carriers with coexistence of HBsAg and anti-HBs based on a community cohort study. J Viral Hepat. 2016 Apr;23(4):286-93. doi: 10.1111/jvh.12492. 
  29. Xiang Y, Chen P, Xia JR, Zhang LP. A large-scale analysis study on the clinical and viral characteristics of hepatitis B infection with concurrence of hepatitis B surface or E antigens and their corresponding antibodies. Genet Mol Res. 2017 Feb 23;16(1). doi: 10.4238/gmr16019102. 

Download Article
Received October 17, 2023.
Accepted November 11, 2023.
©2023 International Medical Research and Development Corporation.